Related references
Note: Only part of the references are listed.Cost of multiple sclerosis in the Czech Republic: The COMS study
J. Blahova Dusankova et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study
Ludwig Kappos et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
Giancarlo Comi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway
Robert H. Scannevin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis
Hiangkiat Tan et al.
ADVANCES IN THERAPY (2011)
The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study
Karsten Beer et al.
BMC NEUROLOGY (2011)
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
Ralf A. Linker et al.
BRAIN (2011)
Potential Health Care Cost Savings Associated With Early Treatment of Multiple Sclerosis Using Disease-Modifying Therapy
Suellen M. Curkendall et al.
CLINICAL THERAPEUTICS (2011)
The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis
V. Devonshire et al.
EUROPEAN JOURNAL OF NEUROLOGY (2011)
Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells
Kamran Ghoreschi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and-23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis
Timothy L. Vollmer et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
Paul O'Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Impact of Adherence to Interferons in the Treatment of Multiple Sclerosis A Non-Experimental, Retrospective, Cohort Study
Stephanie C. Steinberg et al.
CLINICAL DRUG INVESTIGATION (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
Ludwig Kappos et al.
LANCET NEUROLOGY (2009)
Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon β-1b
Carlo Lazzaro et al.
NEUROLOGICAL SCIENCES (2009)
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
Ludwig Kappos et al.
LANCET (2008)
Health-related quality of life in multiple sclerosis: Effects of Natalizumab
Richard A. Rudick et al.
ANNALS OF NEUROLOGY (2007)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Diagnostic criteria for multiple sclerosis: 2005 Revisions to the McDonald Criteria
CH Polman et al.
ANNALS OF NEUROLOGY (2005)
Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents
MP Amato
EXPERT OPINION ON PHARMACOTHERAPY (2004)
Cost of managing an episode of relapse in multiple sclerosis in the United States
JA O'Brien et al.
BMC HEALTH SERVICES RESEARCH (2003)
Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject
DC Mohr et al.
ANNALS OF BEHAVIORAL MEDICINE (2001)
Share Paper
